This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer. This study will provide continued treatment access to subjects with active rheumatoid arthritis who have participated for at least 16 weeks in other studies in the rituximab Pfizer program.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01643928?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
